Dysregulation of synaptic proteins, dendritic spine abnormalities and pathological plasticity of synapses as experience-dependent mediators of cognitive and psychiatric symptoms in Huntington's disease

Neuroscience

Volumn 251, Issue , 2013, Pages 66-74

  Nithianantharajah, J ^a   Hannan, A J ^b  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Cognitive deficits; Huntington's disease; Polyglutamine disease; Psychiatric disorders; Synaptic plasticity; Tandem repeat expansion disorder

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; MEMBRANE PROTEIN; NEUROTRANSMITTER RECEPTOR; NEUROTROPHIN; POLYGLUTAMINE; SCAFFOLD PROTEIN; SYNAPTIC PROTEIN; UNCLASSIFIED DRUG;

BEHAVIOR; BRAIN FUNCTION; COGNITION; COGNITIVE DEFECT; DENDRITIC SPINE; DISEASE MODEL; ENVIRONMENTAL ENRICHMENT; HUMAN; HUNTINGTON CHOREA; LONG TERM POTENTIATION; MENTAL DISEASE; MOLECULAR PATHOLOGY; MOTOR DYSFUNCTION; NERVE CELL PLASTICITY; NEUROMODULATION; NEUROPATHOLOGY; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ACTIN FILAMENTS; BDNF; BRAIN-DERIVED NEUROTROPHIC FACTOR; CAG; COGNITIVE DEFICITS; CYTOSINE-ADENINE-GUANINE TRINUCLEOTIDE; EE; ENVIRONMENTAL ENRICHMENT; F-ACTIN; HD; HTT; HUNTINGTIN; HUNTINGTON'S DISEASE; LONG-TERM DEPRESSION; LONG-TERM POTENTIATION; LTD; LTP; POLYGLUTAMINE DISEASE; POSTSYNAPTIC DENSITY; PSD; PSYCHIATRIC DISORDERS; SYNAPTIC PLASTICITY; TANDEM REPEAT EXPANSION DISORDER; YAC; YEAST ARTIFICIAL CHROMOSOME;

ANIMALS; BRAIN; COGNITION; DENDRITIC SPINES; DISEASE MODELS, ANIMAL; HUMANS; HUNTINGTON DISEASE; MEMBRANE PROTEINS; MICE; NEURONAL PLASTICITY; SYNAPSES;

EID: 84884292211     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2012.05.043     Document Type: Review

References (110)

1. Allen K.L., Waldvogel H.J., Glass M., Faull R.L. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease. J Chem Neuroanat 2009, 37:266-281.
2. Andre V.M., Cepeda C., Levine M.S. Dopamine and glutamate in Huntington's disease: a balancing act. CNS Neurosci Ther 2010, 16:163-178.
3. Ariano M.A., Aronin N., Difiglia M., Tagle D.A., Sibley D.R., Leavitt B.R., Hayden M.R., Levine M.S. Striatal neurochemical changes in transgenic models of Huntington's disease. J Neurosci Res 2002, 68:716-729.
4. Bates G.P., Gonitel R. Mouse models of triplet repeat diseases. Mol Biotechnol 2006, 32:147-158.
5. Bayes A., van de Lagemaat L.N., Collins M.O., Croning M.D., Whittle I.R., Choudhary J.S., Grant S.G. Characterization of the proteome, diseases and evolution of the human postsynaptic density. Nat Neurosci 2011, 14:19-21.
6. Benn C.L., Slow E.J., Farrell L.A., Graham R., Deng Y., Hayden M.R., Cha J.H. Glutamate receptor abnormalities in the YAC128 transgenic mouse model of Huntington's disease. Neuroscience 2007, 147:354-372.
7. Benn C.L., Luthi-Carter R., Kuhn A., Sadri-Vakili G., Blankson K.L., Dalai S.C., Goldstein D.R., Spires T.L., Pritchard J., Olson J.M., van Dellen A., Hannan A.J., Cha J.H. Environmental enrichment reduces neuronal intranuclear inclusion load but has no effect on messenger RNA expression in a mouse model of Huntington disease. J Neuropathol Exp Neurol 2010, 69:817-827.
8. Bowles K.R., Brooks S.P., Dunnett S.B., Jones L. Gene expression and behaviour in mouse models of HD. Brain Res Bull 2011.
9. Bramham C.R., Messaoudi E. BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog Neurobiol 2005, 76:99-125.
10. Brooks S.P., Betteridge H., Trueman R.C., Jones L., Dunnett S.B. Selective extra-dimensional set shifting deficit in a knock-in mouse model of Huntington's disease. Brain Res Bull 2006, 69:452-457.
11. Caramins M., Halliday G., McCusker E., Trent R.J. Genetically confirmed clinical Huntington's disease with no observable cell loss. J Neurol Neurosurg Psychiatry 2003, 74:968-970.
12. Carlisle H.J., Fink A.E., Grant S.G., O'Dell T.J. Opposing effects of PSD-93 and PSD-95 on long-term potentiation and spike timing-dependent plasticity. J Physiol 2008, 586:5885-5900.
13. Cepeda C., Hurst R.S., Calvert C.R., Hernandez-Echeagaray E., Nguyen O.K., Jocoy E., Christian L.J., Ariano M.A., Levine M.S. Transient and progressive electrophysiological alterations in the corticostriatal pathway in a mouse model of Huntington's disease. J Neurosci 2003, 23:961-969.
14. Cepeda C., Starling A.J., Wu N., Nguyen O.K., Uzgil B., Soda T., Andre V.M., Ariano M.A., Levine M.S. Increased GABAergic function in mouse models of Huntington's disease: reversal by BDNF. J Neurosci Res 2004, 78:855-867.
15. Cha J.H. Transcriptional signatures in Huntington's disease. Prog Neurobiol 2007, 83:228-248.
16. Cha J.H., Kosinski C.M., Kerner J.A., Alsdorf S.A., Mangiarini L., Davies S.W., Penney J.B., Bates G.P., Young A.B. Altered brain neurotransmitter receptors in transgenic mice expressing a portion of an abnormal human huntington disease gene. Proc Natl Acad Sci U S A 1998, 95:6480-6485.
17. Cummings D.M., Milnerwood A.J., Dallerac G.M., Waights V., Brown J.Y., Vatsavayai S.C., Hirst M.C., Murphy K.P. Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. Hum Mol Genet 2006, 15:2856-2868.
18. Cummings D.M., Andre V.M., Uzgil B.O., Gee S.M., Fisher Y.E., Cepeda C., Levine M.S. Alterations in cortical excitation and inhibition in genetic mouse models of Huntington's disease. J Neurosci 2009, 29:10371-10386.
19. Desplats P.A., Kass K.E., Gilmartin T., Stanwood G.D., Woodward E.L., Head S.R., Sutcliffe J.G., Thomas E.A. Selective deficits in the expression of striatal-enriched mRNAs in Huntington's disease. J Neurochem 2006, 96:743-757.
20. Ferrante R.J., Kowall N.W., Richardson E.P. Proliferative and degenerative changes in striatal spiny neurons in Huntington's disease: a combined study using the section-Golgi method and calbindin D28k immunocytochemistry. J Neurosci 1991, 11:3877-3887.
21. Ferrer I., Goutan E., Marin C., Rey M.J., Ribalta T. Brain-derived neurotrophic factor in Huntington disease. Brain Res 2000, 866:257-261.
22. Furuyashiki T., Fujisawa K., Fujita A., Madaule P., Uchino S., Mishina M., Bito H., Narumiya S. Citron, a Rho-target, interacts with PSD-95/SAP-90 at glutamatergic synapses in the thalamus. J Neurosci 1999, 19:109-118.
23. Galvan A., Wichmann T. GABAergic circuits in the basal ganglia and movement disorders. Prog Brain Res 2007, 160:287-312.
24. Gauthier L.R., Charrin B.C., Borrell-Pages M., Dompierre J.P., Rangone H., Cordelieres F.P., De Mey J., MacDonald M.E., Lessmann V., Humbert S., Saudou F. Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 2004, 118:127-138.
25. Gibson H.E., Reim K., Brose N., Morton A.J., Jones S. A similar impairment in CA3 mossy fibre LTP in the R6/2 mouse model of Huntington's disease and in the complexin II knockout mouse. Eur J Neurosci 2005, 22:1701-1712.
26. Gines S., Bosch M., Marco S., Gavalda N., Diaz-Hernandez M., Lucas J.J., Canals J.M., Alberch J. Reduced expression of the TrkB receptor in Huntington's disease mouse models and in human brain. Eur J Neurosci 2006, 23:649-658.
27. Goshen I., Avital A., Kreisel T., Licht T., Segal M., Yirmiya R. Environmental enrichment restores memory functioning in mice with impaired IL-1 signaling via reinstatement of long-term potentiation and spine size enlargement. J Neurosci 2009, 29:3395-3403.
28. Grant S.G. Synaptopathies: diseases of the synaptome. Curr Opin Neurobiol 2012.
29. Graveland G.A., Williams R.S., DiFiglia M. Evidence for degenerative and regenerative changes in neostriatal spiny neurons in Huntington's disease. Science 1985, 227:770-773.
30. Gray M., Shirasaki D.I., Cepeda C., Andre V.M., Wilburn B., Lu X.H., Tao J., Yamazaki I., Li S.H., Sun Y.E., Li X.J., Levine M.S., Yang X.W. Full-length human mutant huntingtin with a stable polyglutamine repeat can elicit progressive and selective neuropathogenesis in BACHD mice. J Neurosci 2008, 28:6182-6195.
31. Grote H.E., Bull N.D., Howard M.L., van Dellen A., Blakemore C., Bartlett P.F., Hannan A.J. Cognitive disorders and neurogenesis deficits in Huntington's disease mice are rescued by fluoxetine. Eur J Neurosci 2005, 22:2081-2088.
32. Guidetti P., Charles V., Chen E.Y., Reddy P.H., Kordower J.H., Whetsell W.O., Schwarcz R., Tagle D.A. Early degenerative changes in transgenic mice expressing mutant huntingtin involve dendritic abnormalities but no impairment of mitochondrial energy production. Exp Neurol 2001, 169:340-350.
33. Hannan A.J. Huntington's disease: which drugs might help patients?. IDrugs 2004, 7:351-358.
34. Heck N., Betuing S., Vanhoutte P., Caboche J. A deconvolution method to improve automated 3D-analysis of dendritic spines: application to a mouse model of Huntington's disease. Brain Struct Funct 2011.
35. Heng M.Y., Tallaksen-Greene S.J., Detloff P.J., Albin R.L. Longitudinal evaluation of the Hdh(CAG)150 knock-in murine model of Huntington's disease. J Neurosci 2007, 27:8989-8998.
36. Heng M.Y., Detloff P.J., Wang P.L., Tsien J.Z., Albin R.L. In vivo evidence for NMDA receptor-mediated excitotoxicity in a murine genetic model of Huntington disease. J Neurosci 2009, 29:3200-3205.
37. Hockly E., Cordery P.M., Woodman B., Mahal A., van Dellen A., Blakemore C., Lewis C.M., Hannan A.J., Bates G.P. Environmental enrichment slows disease progression in R6/2 Huntington's disease mice. Ann Neurol 2002, 51:235-242.
38. Hodges A., Strand A.D., Aragaki A.K., Kuhn A., Sengstag T., Hughes G., Elliston L.A., Hartog C., Goldstein D.R., Thu D., Hollingsworth Z.R., Collin F., Synek B., Holmans P.A., Young A.B., Wexler N.S., Delorenzi M., Kooperberg C., Augood S.J., Faull R.L., Olson J.M., Jones L., Luthi-Carter R. Regional and cellular gene expression changes in human Huntington's disease brain. Hum Mol Genet 2006, 15:965-977.
39. Hodges A., Hughes G., Brooks S., Elliston L., Holmans P., Dunnett S.B., Jones L. Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington's disease. Genes Brain Behav 2008, 7:288-299.
40. Hodgson J.G., Agopyan N., Gutekunst C.A., Leavitt B.R., LePiane F., Singaraja R., Smith D.J., Bissada N., McCutcheon K., Nasir J., Jamot L., Li X.J., Stevens M.E., Rosemond E., Roder J.C., Phillips A.G., Rubin E.M., Hersch S.M., Hayden M.R. A YAC mouse model for Huntington's disease with full-length mutant huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 1999, 23:181-192.
41. Ichtchenko K., Hata Y., Nguyen T., Ullrich B., Missler M., Moomaw C., Sudhof T.C. Neuroligin 1: a splice site-specific ligand for beta-neurexins. Cell 1995, 81:435-443.
42. Ickes B.R., Pham T.M., Sanders L.A., Albeck D.S., Mohammed A.H., Granholm A.C. Long-term environmental enrichment leads to regional increases in neurotrophin levels in rat brain. Exp Neurol 2000, 164:45-52.
43. Irie M., Hata Y., Takeuchi M., Ichtchenko K., Toyoda A., Hirao K., Takai Y., Rosahl T.W., Sudhof T.C. Binding of neuroligins to PSD-95. Science 1997, 277:1511-1515.
44. Jarabek B.R., Yasuda R.P., Wolfe B.B. Regulation of proteins affecting NMDA receptor-induced excitotoxicity in a Huntington's mouse model. Brain 2004, 127:505-516.
45. Josiassen R.C., Curry L.M., Mancall E.L. Development of neuropsychological deficits in Huntington's disease. Arch Neurol 1983, 40:791-796.
46. Klapstein G.J., Fisher R.S., Zanjani H., Cepeda C., Jokel E.S., Chesselet M.F., Levine M.S. Electrophysiological and morphological changes in striatal spiny neurons in R6/2 Huntington's disease transgenic mice. J Neurophysiol 2001, 86:2667-2677.
47. Kuhn A., Goldstein D.R., Hodges A., Strand A.D., Sengstag T., Kooperberg C., Becanovic K., Pouladi M.A., Sathasivam K., Cha J.H., Hannan A.J., Hayden M.R., Leavitt B.R., Dunnett S.B., Ferrante R.J., Albin R., Shelbourne P., Delorenzi M., Augood S.J., Faull R.L., Olson J.M., Bates G.P., Jones L., Luthi-Carter R. Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. Hum Mol Genet 2007, 16:1845-1861.
48. Lawrence A.D., Sahakian B.J., Hodges J.R., Rosser A.E., Lange K.W., Robbins T.W. Executive and mnemonic functions in early Huntington's disease. Brain 1996, 119:1633-1645.
49. Lawrence A.D., Hodges J.R., Rosser A.E., Kershaw A., ffrench-Constant C., Rubinsztein D.C., Robbins T.W., Sahakian B.J. Evidence for specific cognitive deficits in preclinical Huntington's disease. Brain 1998, 121:1329-1341.
50. Lawrence A.D., Sahakian B.J., Rogers R.D., Hodge J.R., Robbins T.W. Discrimination, reversal, and shift learning in Huntington's disease: mechanisms of impaired response selection. Neuropsychologia 1999, 37:1359-1374.
51. Lawrence A.D., Watkins L.H., Sahakian B.J., Hodges J.R., Robbins T.W. Visual object and visuospatial cognition in Huntington's disease: implications for information processing in corticostriatal circuits. Brain 2000, 123:1349-1364.
52. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., Dom R. Longitudinal study evaluating neuropsychological changes in so-called asymptomatic carriers of the Huntington's disease mutation after 1 year. Acta Neurol Scand 2002, 106:131-141.
53. Lemiere J., Decruyenaere M., Evers-Kiebooms G., Vandenbussche E., Dom R. Cognitive changes in patients with Huntington's disease (HD) and asymptomatic carriers of the HD mutation - a longitudinal follow-up study. J Neurol 2004, 251:935-942.
54. Levine M.S., Klapstein G.J., Koppel A., Gruen E., Cepeda C., Vargas M.E., Jokel E.S., Carpenter E.M., Zanjani H., Hurst R.S., Efstratiadis A., Zeitlin S., Chesselet M.F. Enhanced sensitivity to N-methyl-D-aspartate receptor activation in transgenic and knockin mouse models of Huntington's disease. J Neurosci Res 1999, 58:515-532.
55. Lin C.H., Tallaksen-Greene S., Chien W.M., Cearley J.A., Jackson W.S., Crouse A.B., Ren S., Li X.J., Albin R.L., Detloff P.J. Neurological abnormalities in a knock-in mouse model of Huntington's disease. Hum Mol Genet 2001, 10:137-144.
56. Lione L.A., Carter R.J., Hunt M.J., Bates G.P., Morton A.J., Dunnett S.B. Selective discrimination learning impairments in mice expressing the human Huntington's disease mutation. J Neurosci 1999, 19:10428-10437.
57. Luthi-Carter R., Strand A., Peters N.L., Solano S.M., Hollingsworth Z.R., Menon A.S., Frey A.S., Spektor B.S., Penney E.B., Schilling G., Ross C.A., Borchelt D.R., Tapscott S.J., Young A.B., Cha J.H., Olson J.M. Decreased expression of striatal signaling genes in a mouse model of Huntington's disease. Hum Mol Genet 2000, 9:1259-1271.
58. Luthi-Carter R., Apostol B.L., Dunah A.W., DeJohn M.M., Farrell L.A., Bates G.P., Young A.B., Standaert D.G., Thompson L.M., Cha J.H. Complex alteration of NMDA receptors in transgenic Huntington's disease mouse brain: analysis of mRNA and protein expression, plasma membrane association, interacting proteins, and phosphorylation. Neurobiol Dis 2003, 14:624-636.
59. Lynch G., Kramar E.A., Rex C.S., Jia Y., Chappas D., Gall C.M., Simmons D.A. Brain-derived neurotrophic factor restores synaptic plasticity in a knock-in mouse model of Huntington's disease. J Neurosci 2007, 27:4424-4434.
60. Lynch G., Rex C.S., Gall C.M. LTP consolidation: substrates, explanatory power, and functional significance. Neuropharmacology 2007, 52:12-23.
61. Mangiarini L., Sathasivam K., Seller M., Cozens B., Harper A., Hetherington C., Lawton M., Trottier Y., Lehrach H., Davies S.W., Bates G.P. Exon 1 of the HD gene with an expanded CAG repeat is sufficient to cause a progressive neurological phenotype in transgenic mice. Cell 1996, 87:493-506.
62. Mazarakis N.K., Cybulska-Klosowicz A., Grote H., Pang T., Van Dellen A., Kossut M., Blakemore C., Hannan A.J. Deficits in experience-dependent cortical plasticity and sensory-discrimination learning in presymptomatic Huntington's disease mice. J Neurosci 2005, 25:3059-3066.
63. McOmish C.E., Hannan A.J. Enviromimetics: exploring gene environment interactions to identify therapeutic targets for brain disorders. Expert Opin Ther Targets 2007, 11:899-913.
64. Migaud M., Charlesworth P., Dempster M., Webster L.C., Watabe A.M., Makhinson M., He Y., Ramsay M.F., Morris R.G., Morrison J.H., O'Dell T.J., Grant S.G. Enhanced long-term potentiation and impaired learning in mice with mutant postsynaptic density-95 protein. Nature 1998, 396:433-439.
65. Milnerwood A.J., Raymond L.A. Early synaptic pathophysiology in neurodegeneration: insights from Huntington's disease. Trends Neurosci 2010, 33:513-523.
66. Milnerwood A.J., Cummings D.M., Dallerac G.M., Brown J.Y., Vatsavayai S.C., Hirst M.C., Rezaie P., Murphy K.P. Early development of aberrant synaptic plasticity in a mouse model of Huntington's disease. Hum Mol Genet 2006, 15:1690-1703.
67. Murphy K.P., Carter R.J., Lione L.A., Mangiarini L., Mahal A., Bates G.P., Dunnett S.B., Morton A.J. Abnormal synaptic plasticity and impaired spatial cognition in mice transgenic for exon 1 of the human Huntington's disease mutation. J Neurosci 2000, 20:5115-5123.
68. Niethammer M., Valtschanoff J.G., Kapoor T.M., Allison D.W., Weinberg R.J., Craig A.M., Sheng M. CRIPT, a novel postsynaptic protein that binds to the third PDZ domain of PSD-95/SAP90. Neuron 1998, 20:693-707.
69. Nithianantharajah J., Hannan A.J. Enriched environments, experience-dependent plasticity and disorders of the nervous system. Nat Rev Neurosci 2006, 7:697-709.
70. Nithianantharajah J., Hannan A.J. The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog Neurobiol 2009, 89:369-382.
71. Nithianantharajah J., Barkus C., Murphy M., Hannan A.J. Gene-environment interactions modulating cognitive function and molecular correlates of synaptic plasticity in Huntington's disease transgenic mice. Neurobiol Dis 2008, 29:490-504.
72. Nithianantharajah J., Barkus C., Vijiaratnam N., Clement O., Hannan A.J. Modeling brain reserve: experience-dependent neuronal plasticity in healthy and Huntington's disease transgenic mice. Am J Geriatr Psychiatry 2009, 17:196-209.
73. O'Callaghan R.M., Griffin E.W., Kelly A.M. Long-term treadmill exposure protects against age-related neurodegenerative change in the rat hippocampus. Hippocampus 2009.
74. Pang T.Y., Stam N.C., Nithianantharajah J., Howard M.L., Hannan A.J. Differential effects of voluntary physical exercise on behavioral and brain-derived neurotrophic factor expression deficits in Huntington's disease transgenic mice. Neuroscience 2006, 141:569-584.
75. Pang T.Y., Du X., Zajac M.S., Howard M.L., Hannan A.J. Altered serotonin receptor expression is associated with depression-related behavior in the R6/1 transgenic mouse model of Huntington's disease. Hum Mol Genet 2009, 18:753-766.
76. Rampon C., Jiang C.H., Dong H., Tang Y.P., Lockhart D.J., Schultz P.G., Tsien J.Z., Hu Y. Effects of environmental enrichment on gene expression in the brain. Proc Natl Acad Sci U S A 2000, 97:12880-12884.
77. Raymond L.A., Andre V.M., Cepeda C., Gladding C.M., Milnerwood A.J., Levine M.S. Pathophysiology of Huntington's disease: time-dependent alterations in synaptic and receptor function. Neuroscience 2011, 198:252-273.
78. Rex C.S., Lin C.Y., Kramar E.A., Chen L.Y., Gall C.M., Lynch G. Brain-derived neurotrophic factor promotes long-term potentiation-related cytoskeletal changes in adult hippocampus. J Neurosci 2007, 27:3017-3029.
79. Richards P., Didszun C., Campesan S., Simpson A., Horley B., Young K.W., Glynn P., Cain K., Kyriacou C.P., Giorgini F., Nicotera P. Dendritic spine loss and neurodegeneration is rescued by Rab11 in models of Huntington's disease. Cell Death Differ 2011, 18:191-200.
80. Runne H., Regulier E., Kuhn A., Zala D., Gokce O., Perrin V., Sick B., Aebischer P., Deglon N., Luthi-Carter R. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry. J Neurosci 2008, 28:9723-9731.
81. Schilling G., Savonenko A.V., Coonfield M.L., Morton J.L., Vorovich E., Gale A., Neslon C., Chan N., Eaton M., Fromholt D., Ross C.A., Borchelt D.R. Environmental, pharmacological, and genetic modulation of the HD phenotype in transgenic mice. Exp Neurol 2004, 187:137-149.
82. Shelbourne P.F., Killeen N., Hevner R.F., Johnston H.M., Tecott L., Lewandoski M., Ennis M., Ramirez L., Li Z., Iannicola C., Littman D.R., Myers R.M. A Huntington's disease CAG expansion at the murine Hdh locus is unstable and associated with behavioural abnormalities in mice. Hum Mol Genet 1999, 8:763-774.
83. Simmons D.A., Rex C.S., Palmer L., Pandyarajan V., Fedulov V., Gall C.M., Lynch G. Up-regulating BDNF with an ampakine rescues synaptic plasticity and memory in Huntington's disease knockin mice. Proc Natl Acad Sci U S A 2009, 106:4906-4911.
84. Slow E.J., van Raamsdonk J., Rogers D., Coleman S.H., Graham R.K., Deng Y., Oh R., Bissada N., Hossain S.M., Yang Y.Z., Li X.J., Simpson E.M., Gutekunst C.A., Leavitt B.R., Hayden M.R. Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease. Hum Mol Genet 2003, 12:1555-1567.
85. Smith A.D., Zigmond M.J. Can the brain be protected through exercise? Lessons from an animal model of parkinsonism. Exp Neurol 2003, 184:31-39.
86. Song J.Y., Ichtchenko K., Sudhof T.C., Brose N. Neuroligin 1 is a postsynaptic cell-adhesion molecule of excitatory synapses. Proc Natl Acad Sci U S A 1999, 96:1100-1105.
87. Sotrel A., Williams R.S., Kaufmann W.E., Myers R.H. Evidence for neuronal degeneration and dendritic plasticity in cortical pyramidal neurons of Huntington's disease: a quantitative Golgi study. Neurology 1993, 43:2088-2096.
88. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., Hannan A.J. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J Neurosci 2004, 24:2270-2276.
89. Spires T.L., Grote H.E., Garry S., Cordery P.M., Van Dellen A., Blakemore C., Hannan A.J. Dendritic spine pathology and deficits in experience-dependent dendritic plasticity in R6/1 Huntington's disease transgenic mice. Eur J Neurosci 2004, 19:2799-2807.
90. Squitieri F., Cannella M., Simonelli M., Sassone J., Martino T., Venditti E., Ciammola A., Colonnese C., Frati L., Ciarmiello A. Distinct brain volume changes correlating with clinical stage, disease progression rate, mutation size, and age at onset prediction as early biomarkers of brain atrophy in Huntington's disease. CNS Neurosci Ther 2009, 15:1-11.
91. Stein V., House D.R., Bredt D.S., Nicoll R.A. Postsynaptic density-95 mimics and occludes hippocampal long-term potentiation and enhances long-term depression. J Neurosci 2003, 23:5503-5506.
92. Sugars K.L., Rubinsztein D.C. Transcriptional abnormalities in Huntington disease. Trends Genet 2003, 19:233-238.
93. Thompson-Vest N.M., Waldvogel H.J., Rees M.I., Faull R.L. GABA(A) receptor subunit and gephyrin protein changes differ in the globus pallidus in Huntington's diseased brain. Brain Res 2003, 994:265-270.
94. Torasdotter M., Metsis M., Henriksson B.G., Winblad B., Mohammed A.H. Environmental enrichment results in higher levels of nerve growth factor mRNA in the rat visual cortex and hippocampus. Behav Brain Res 1998, 93:83-90.
95. Turmaine M., Raza A., Mahal A., Mangiarini L., Bates G.P., Davies S.W. Nonapoptotic neurodegeneration in a transgenic mouse model of Huntington's disease. Proc Natl Acad Sci U S A 2000, 97:8093-8097.
96. Twelvetrees A.E., Yuen E.Y., Arancibia-Carcamo I.L., MacAskill A.F., Rostaing P., Lumb M.J., Humbert S., Triller A., Saudou F., Yan Z., Kittler J.T. Delivery of GABAARs to synapses is mediated by HAP1-KIF5 and disrupted by mutant huntingtin. Neuron 2010, 65:53-65.
97. Usdin M.T., Shelbourne P.F., Myers R.M., Madison D.V. Impaired synaptic plasticity in mice carrying the Huntington's disease mutation. Hum Mol Genet 1999, 8:839-846.
98. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
99. van Praag H., Kempermann G., Gage F.H. Neural consequences of environmental enrichment. Nat Rev Neurosci 2000, 1:191-198.
100. Van Raamsdonk J.M., Pearson J., Slow E.J., Hossain S.M., Leavitt B.R., Hayden M.R. Cognitive dysfunction precedes neuropathology and motor abnormalities in the YAC128 mouse model of Huntington's disease. J Neurosci 2005, 25:4169-4180.
101. von Horsten S., Schmitt I., Nguyen H.P., Holzmann C., Schmidt T., Walther T., Bader M., Pabst R., Kobbe P., Krotova J., Stiller D., Kask A., Vaarmann A., Rathke-Hartlieb S., Schulz J.B., Grasshoff U., Bauer I., Vieira-Saecker A.M., Paul M., Jones L., Lindenberg K.S., Landwehrmeyer B., Bauer A., Li X.J., Riess O. Transgenic rat model of Huntington's disease. Hum Mol Genet 2003, 12:617-624.
102. Wheeler V.C., White J.K., Gutekunst C.A., Vrbanac V., Weaver M., Li X.J., Li S.H., Yi H., Vonsattel J.P., Gusella J.F., Hersch S., Auerbach W., Joyner A.L., MacDonald M.E. Long glutamine tracts cause nuclear localization of a novel form of huntingtin in medium spiny striatal neurons in HdhQ92 and HdhQ111 knock-in mice. Hum Mol Genet 2000, 9:503-513.
103. White J.K., Auerbach W., Duyao M.P., Vonsattel J.P., Gusella J.F., Joyner A.L., MacDonald M.E. Huntingtin is required for neurogenesis and is not impaired by the Huntington's disease CAG expansion. Nat Genet 1997, 17:404-410.
104. Xie Y., Hayden M.R., Xu B. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice. J Neurosci 2011, 30:14708-14718.
105. Zajac M.S., Pang T.Y., Wong N., Weinrich B., Leang L.S., Craig J.M., Saffery R., Hannan A.J. Wheel running and environmental enrichment differentially modify exon-specific BDNF expression in the hippocampus of wild-type and pre-motor symptomatic male and female Huntington's disease mice. Hippocampus 2010, 20:621-636.
106. Zhang W., Vazquez L., Apperson M., Kennedy M.B. Citron binds to PSD-95 at glutamatergic synapses on inhibitory neurons in the hippocampus. J Neurosci 1999, 19:96-108.
107. Zhu S.W., Yee B.K., Nyffeler M., Winblad B., Feldon J., Mohammed A.H. Influence of differential housing on emotional behaviour and neurotrophin levels in mice. Behav Brain Res 2006, 169:10-20.
108. Zuccato C., Cattaneo E. Brain-derived neurotrophic factor in neurodegenerative diseases. Nat Rev 2009, 5:311-322.
109. Zuccato C., Ciammola A., Rigamonti D., Leavitt B.R., Goffredo D., Conti L., MacDonald M.E., Friedlander R.M., Silani V., Hayden M.R., Timmusk T., Sipione S., Cattaneo E. Loss of huntingtin-mediated BDNF gene transcription in Huntington's disease. Science 2001, 293:493-498.
110. Zuccato C., Tartari M., Crotti A., Goffredo D., Valenza M., Conti L., Cataudella T., Leavitt B.R., Hayden M.R., Timmusk T., Rigamonti D., Cattaneo E. Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes. Nat Genet 2003, 35:76-83.